Ipsen's Bylvay Fails Primary Endpoint in Phase III Biliary Atresia Trial
Event summary
- Ipsen's Phase III BOLD trial for Bylvay (odevixibat) in biliary atresia failed to meet the primary endpoint of improving native liver survival vs. placebo.
- The trial enrolled 254 patients across 19 countries, making it the largest study evaluating disease modification in biliary atresia.
- Bylvay is already approved for cholestatic pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
- An open-label extension study (BOLD-EXT) is ongoing to evaluate longer-term safety and efficacy of odevixibat.
The big picture
Ipsen's failure in the BOLD trial highlights the persistent challenges in developing effective medical treatments for biliary atresia, a rare pediatric liver disease with limited therapeutic options. The setback underscores the complexity of targeting this heterogeneous condition and may prompt re-evaluation of Ipsen's strategy in the rare disease space.
What we're watching
- Pipeline Strategy
- How Ipsen will pivot its rare disease pipeline following this setback in biliary atresia.
- Regulatory Impact
- Whether the trial results affect Bylvay's existing approvals for PFIC and ALGS.
- Competitive Dynamics
- The pace at which competitors advance alternative treatments for biliary atresia.